152 related articles for article (PubMed ID: 8205134)
1. Development of radioimmunoassay for the novel platelet activating factor receptor antagonist, E6123, and its application to pharmacokinetics in laboratory animals.
Kusano K; Tadano K; Tanaka S; Kagei Y; Ueda M; Miyazawa S; Abe Y; Ida S; Yuzuriha T
Biol Pharm Bull; 1994 Feb; 17(2):334-9. PubMed ID: 8205134
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of a new thienodiazepine platelet activating factor receptor antagonist (E6123) in laboratory animals. Is there a metabolic polymorphism in the rhesus monkey?
Kusano K; Tanaka S; Abe Y; Ida S; Yuzuriha T
Xenobiotica; 1993 Jun; 23(6):589-98. PubMed ID: 8212733
[TBL] [Abstract][Full Text] [Related]
3. Metabolic polymorphism of E6123 in rhesus monkey.
Kusano K; Tanaka S; Ando T; Abe Y; Ida S; Yuzuriha T
Xenobiotica; 1993 Jun; 23(6):599-608. PubMed ID: 8212734
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunoassay for the novel platelet activating factor receptor antagonist E5880.
Suzuki H; Asano O; Tadano K; Horie T
J Pharm Sci; 1994 May; 83(5):657-61. PubMed ID: 8071816
[TBL] [Abstract][Full Text] [Related]
5. Hapten synthesis for (+)-6-(2-chlorophenyl)-3-cyclopropanecarbonyl-8,11-dimethyl-2,3,4,5-tet rahydro-8H-pyrido[4',3':4,5]thieno[3,2-f] triazolo[4,3-a][1,4]diazepine (E6123).
Miyazawa S; Okano K; Kawahara T; Machida Y; Yamatsu I
Chem Pharm Bull (Tokyo); 1992 Mar; 40(3):762-5. PubMed ID: 1611690
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of a novel PAF antagonist E6123 on anaphylactic responses in passively and actively sensitized guinea pigs and passively sensitized mice.
Sakuma Y; Muramoto K; Harada K; Katayama S; Tsunoda H; Katayama K
Prostaglandins; 1991 Dec; 42(6):541-55. PubMed ID: 1801063
[TBL] [Abstract][Full Text] [Related]
7. Effects of a novel PAF antagonist, E6123, on PAF-induced biological responses.
Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K
Agents Actions Suppl; 1990; 31():251-4. PubMed ID: 2080757
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological effects of oral E6123, a novel PAF antagonist, on biological changes induced by PAF inhalation in guinea pigs.
Sakuma Y; Tsunoda H; Shirato M; Katayama S; Yamatsu I; Katayama K
Prostaglandins; 1991 Nov; 42(5):463-72. PubMed ID: 1763202
[TBL] [Abstract][Full Text] [Related]
9. Effects of a novel PAF antagonist, E6123, on passive anaphylaxis.
Sakuma Y; Tsunoda H; Katayama S; Harada K; Obaishi H; Shirato M; Yamada K; Miyazawa S; Okano K; Machida Y
Agents Actions Suppl; 1990; 31():255-8. PubMed ID: 2080758
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K
Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal physiology-regulated dogs: utilization of a bioavailability study of a new thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]-diazepine, an antagonist of platelet-activating factor, and its preparations.
Sagara K; Yamada I; Kawazoe Y; Mizuta H; Shibata M
Biol Pharm Bull; 1994 Jan; 17(1):117-20. PubMed ID: 8148798
[TBL] [Abstract][Full Text] [Related]
12. Brotizolam radioimmunoassay: development, evaluation, and application to human plasma samples.
Bechtel WD; Weber KH
J Pharm Sci; 1985 Dec; 74(12):1265-9. PubMed ID: 4087192
[TBL] [Abstract][Full Text] [Related]
13. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunoassay for DS-4574, an antiallergic agent: development, evaluation, and application to human plasma samples.
Murayama N; Nakaoka M; Nomura H; Hakusui H
J Pharm Sci; 1994 Nov; 83(11):1574-7. PubMed ID: 7891277
[TBL] [Abstract][Full Text] [Related]
15. Triprolidine radioimmunoassay: disposition in animals and humans.
Findlay JW; Butz RF; Coker GG; DeAngelis RL; Welch RM
J Pharm Sci; 1984 Oct; 73(10):1339-44. PubMed ID: 6502476
[TBL] [Abstract][Full Text] [Related]
16. Aprikalim: radioimmunoassay and pharmacokinetic studies in mouse, monkey, and dog.
Chevalier P; Rouillard C; Montay G; Frydman A
J Pharm Sci; 1994 Mar; 83(3):372-8. PubMed ID: 8207684
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
Ring PC; Seldon PM; Barnes PJ; Giembycz MA
Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.
Brecht HM; Adamus WS; Heuer HO; Birke FW; Kempe ER
Arzneimittelforschung; 1991 Jan; 41(1):51-9. PubMed ID: 1646613
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity studies on triazolothienodiazepine derivatives as platelet-activating factor antagonists.
Miyazawa S; Okano K; Shimomura N; Clark RS; Kawahara T; Asano O; Yoshimura H; Miyamoto M; Sakuma Y; Muramoto K
Chem Pharm Bull (Tokyo); 1991 Dec; 39(12):3215-20. PubMed ID: 1814614
[TBL] [Abstract][Full Text] [Related]
20. Determination of the anti-platelet-activating factor BN-50727 and its metabolites in human plasma by high-performance liquid chromatography-solid-phase extraction.
Pruñonosa J; Parera L; Peraire C; Pla F; Lavergne O; Obach R
J Chromatogr B Biomed Appl; 1995 Jun; 668(2):281-90. PubMed ID: 7581863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
